ArticleMedical decision making : an international journal of the Society for Medical Decision Making2018
Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.
Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Mathematical Modeling to Address Questions in Breast Cancer Screening: An Overview of the Breast Cancer Models of the Cancer Intervention and Surveillance Modeling Network.Journal of breast imaging · 2025Review
- The Landscape of Breast Cancer Molecular and Histologic Subtypes in Canada.Current oncology (Toronto, Ont.) · 2024Article
- Article
- Population simulation modeling of disparities in US breast cancer mortality.Journal of the National Cancer Institute. Monographs · 2023Article
- Diagnosis and prognosis prediction model for digestive system tumors based on immunologic gene sets.Frontiers in oncology · 2023Article
- Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.BMC cancer · 2022Article
- Motivation Research on the Content Creation Behaviour of Young Adults in Anxiety Disorder Online Communities.International journal of environmental research and public health · 2021Article
- Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts.PLoS computational biology · 2021Review
- Immune Cell Infiltration as Signatures for the Diagnosis and Prognosis of Malignant Gynecological Tumors.Frontiers in cell and developmental biology · 2021Article
- Article
- Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States.Journal of the National Cancer Institute · 2020Article
- Adjuvant Chemotherapy for Older Patients With Breast Cancer: When Is the Pain Worth the Gain?Journal of the National Cancer Institute · 2020Article
- Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.Journal of the National Cancer Institute · 2020Article
- Breast Cancer Incidence Trends by Estrogen Receptor Status Among Asian American Ethnic Groups, 1990-2014.JNCI cancer spectrum · 2020Article
- Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Article
- A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Article
- Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Article
- Cost Effectiveness of Gene Expression Profile Testing in Community Practice.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.Breast cancer research and treatment · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAs molecular subtyping of breast cancer influences clinical management, the evaluation of screening and adjuvant treatment interventions at the population level needs to account for molecular subtyping. Performing such analyses are challenging because molecular subtype-specific, long-term outcomes are not readily accessible; these markers were not historically recorded in tumor registries. We present a modeling approach to estimate historical survival outcomes by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status.
methodOur approach leverages a simulation model of breast cancer outcomes and integrates data from two sources: the Surveillance Epidemiology and End Results (SEER) databases and the Breast Cancer Surveillance Consortium (BCSC). We not only produce ER- and HER2-specific estimates of breast cancer survival in the absence of screening and adjuvant treatment but we also estimate mean tumor volume doubling time (TVDT) and mean mammographic detection threshold by ER/HER2-status.
resultsIn general, we found that tumors with ER-negative and HER2-positive status are associated with more aggressive growth, have lower TVDTs, are harder to detect by mammography, and have worse survival outcomes in the absence of screening and adjuvant treatment. Our estimates have been used as inputs into model-based analyses that evaluate the effects of screening and adjuvant treatment interventions on population outcomes by ER and HER2 status developed by the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Working Group. In addition, our estimates enable a re-assessment of historical trends in breast cancer incidence and mortality in terms of contemporary molecular tumor characteristics.
conclusionOur approach can be generalized beyond breast cancer and to more complex molecular profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.